Introduction {#S1}
============

Acute renal failure (ARF) is a frequent complication in patients with cancer. It may develop due to the cancer itself (multiple myeloma, neoplastic urinary tract obstruction, renal malignant infiltration), its treatment (nephrotoxic chemotherapy, tumor lysis syndrome ...), or secondary complication (sepsis, nephrotoxic antibiotics, iodine contrast administration ...) ([@B1], [@B2]). Up to 54% of patients with cancer admitted to the intensive care unit (ICU) develop ARF and some require renal replacement therapy (RRT) ([@B3]--[@B5]). Despite improvements in the general management of ICU patients with cancer, ARF worsens the prognosis. In patient with cancer requiring dialysis, hospital mortality rates are reported between 51 and 90% ([@B6]--[@B8]).

A few published studies are dealing with outcome of patients with cancer with ARF, who required RRT. Results are difficult to compare for several reasons as types and indications of RRT largely varying from one study to another or populations are not comparable. For example, the proportion of solid and hematologic tumors and the number of hematological transplantation were inconstant across the studies while these patients are carrying very distinct prognosis ([@B7]--[@B14]).

In a first study performed at the Bordet Institute, continuous venovenous hemodiafiltration (CVVHDF) was shown effective for the treatment of ARF in patients with cancer, including solid and hematologic tumors as well as auto- and allograft recipients ([@B15]). In the latter small retrospective study, the single independent poor prognostic factor for hospital mortality was the increasing number of organ failures. In another study with a similar case-mix, other authors confirmed the prognostic role of the number of organ failures on hospital mortality ([@B16]). As dialysis techniques evolve with time, we aimed at confirming our previously published results on the effectiveness of RRT in a larger cohort of patients with cancer. The primary objective of this retrospective study was the search of prognostic factors for hospital mortality in this group of patients that could eventually help in guiding decision of RRT.

Patients and Methods {#S2}
====================

All consecutive patients admitted in the medical ICU of the Institut Jules Bordet between January 1, 2003 and December 31, 2012 were recorded. The records of the patients with ARF requiring continuous venovenous RRT at admission or during ICU stay were retrospectively reviewed. Only the first episode of ARF requiring RRT was taken into account. Patients with end-stage renal diseases requiring chronic dialysis were excluded. The study was approved by the ethical committee of the Institut Jules Bordet.

Acute renal failure was defined as a creatinine increase \>2 mg/dl (176 μmol/l) in case of pre-existing normal value, or an increase \>1 mg/dl from the basic value in case of chronic renal failure. Decision for CVVHDF was based on one (or more) of the following characteristics: bicarbonate level \<10 mg/dl, metabolic acidosis (pH \<7.30), uremia \>33.2 mmol/l, kaliemia \>6 mEq/dl, water overload, pericarditis secondary to ARF, uremic encephalitis, severe ionic abnormalities (hyponatremia, hyperphosphoremia), oligoanuria in presence of evolutive ARF.

The following clinical data were retrieved from the patient's charts: gender, age, type of cancer, cancer phase ([@B17]) (diagnostic, curative, controllable but no more curable, pivotal or palliative), cancer status ([@B18]) (disease under induction therapy, complete remission without or on active anti-cancer treatment, partial remission, stable disease, progression), reason for ICU admission, anticancer treatments including bone marrow transplantation, potential nephrotoxic agents (iodine contrast agent, antibiotics, chemotherapy ...), co-morbidities, ARF etiology, reason for CVVHDF, variables used for the computation of Simplified Acute Physiology Score II (SAPS II) ([@B19]).

The following data were collected at start of RRT: furosemide and vasopressive drugs administration, diuresis, blood pressure, heart and respiratory rates, temperature, biological variables, number of organ failures (including renal failure) at the time of ARF, the immunosuppression status according to the Organ Dysfunction and/or Infection (ODIN) score, the presence of an acute respiratory distress syndrome, and mechanical ventilation support.

We also recorded the main characteristics of RRT: duration, CVVHDF parameters, CVVHDF complications. To determine the final outcome of the patient, we assessed the renal function status (complete, partial or absence of return to initial creatinine values), mortality rates (during hospital and ICU stays), the date and cause of death, or last date known to be alive.

Statistics and Data Analysis {#S2-1}
----------------------------

Results are reported as medians and range. Prognostic factors for hospital mortality were tested in univariate analysis. Binary variables were compared by chi-square test or Fischer's exact test. Non-parametric Mann--Whitney tests were used to compare continuous variables. Variables yielding *p* value less or equal to 0.2 in univariate analysis were entered into a multiple logistic regression. A Hosmer--Lemeshow test was performed to verify the goodness of fit. A *p* value \<0.05 was considered statistically significant.

Results {#S3}
=======

One-hundred and twelve patients were treated with RRT during the study period. One patient on chronic dialysis was excluded. Incomplete charts led to exclusion of a further 8 cases leaving 103 patients assessable for the final analysis.

The principal characteristics of the population are reported in Table [1](#T1){ref-type="table"}. Renal failure primarily of renal origin, occurred in 83 patients, obstructive renal failure in 1 patient and both types combined in 19 patients. Etiologies of renal failure from renal origin were miscellaneous and detailed in Table [2](#T2){ref-type="table"}. A combination of nephrotoxic insults was observed in 43 patients (42%). A number of potentially nephrotoxic drugs were implicated in the development of renal failure: antibiotics/antifungals/antivirals (*n* = 45), non-steroidal anti-inflammatory (*n* = 15), iodine contrast product (*n* = 15), chemotherapy agents (*n* = 12), furosemide (dose ≥500 mg/24 h) (*n* = 10), ciclosporine/sirolimus (*n* = 9), sartan/ACE inhibitor (*n* = 4), zoledronic acid/OKT3 (*n* = 2). A combination of nephrotoxics was found in 31 cases.

###### 

**Characteristics at ICU admission of 103 patients with cancer with acute renal failure requiring renal replacement therapy**.

  -------------------------------------------------------------- -------------------
  Sex (male/female)                                              69/34 (67%/33%)
  Age (median/range)                                             62 years (19--87)
  Solid malignancies (locoregional/metastatic)                   68 (66%) (28/40)
   Breast                                                        7 (7%)
   Lung                                                          6 (6%)
   Digestive tract                                               15 (15%)
   Prostate/bladder/kidney                                       23 (22%)
   Other                                                         17 (17%)
  Hematological malignancies                                     35 (34%)
   Leukemia                                                      10 (10%)
   Lymphoma                                                      14 (14%)
   Multiple myeloma                                              9 (9%)
   Myelodysplastic syndrome                                      2 (2%)
  Stem cell transplantation before ICU admission (allo/auto)     18 (14/4) (17%)
  Cancer phase                                                   
   Diagnostic                                                    9 (9%)
   Curative                                                      41 (40%)
   Controllable                                                  53 (51%)
  Cancer status                                                  
   Induction                                                     25 (24%)
   Diagnostic                                                    9 (9%)
   Remission (partial or complete)                               35 (34%)
   Stabilization                                                 1 (1%)
   Progression                                                   33 (32%)
  Causes of ICU admission                                        
   Renal disease                                                 58 (56%)
   Shock/sepsis                                                  20 (19%)
   Metabolic disorder                                            9 (9%)
   Respiratory failure                                           8 (8%)
   Other                                                         8 (8%)
  Chemotherapy given before ICU admission                        
   Less than 15 days                                             35 (34%)
   More than 15 days                                             27 (26%)
   No                                                            41 (40%)
  Immunodepression                                               50 (49%)
  Urinary tract infection                                        14 (14%)
  Diabetes                                                       14 (14%)
  Baseline characteristics at the time of initiation of CVVHDF   
   ARDS                                                          25 (24%)
   Mechanical ventilation                                        53 (51%)
   Vasopressors                                                  43 (42%)
   Hematological failure                                         28 (27%)
   \>1 organ failure                                             65 (63%)
   pH (median/range)                                             7.3 (7.02--7.52)
   Natremia (mEq/l) (median/range)                               138 (122--150)
   Kaliemia (mEq/l) (median/range)                               4.7 (2.9--8)
   Creatininemia (mg/dl) (median/range)                          3.76 (1.28--20.1)
   Uremia (mg/dl) (median/range)                                 151 (49--492)
  SAPS II (median/range)                                         56 (28--99)
  -------------------------------------------------------------- -------------------

*ICU, intensive care unit; SAPS, simplified acute physiology score; allo, allogenic; auto, autologous; ARDS, acute respiratory distress syndrome*.

###### 

**Principal etiologies of acute renal failure in patients admitted in the ICU**.

                                                            *n*   \%[^a^](#tfn1){ref-type="table-fn"}
  --------------------------------------------------------- ----- -------------------------------------
  Nephrotoxic drugs                                         48    47
  Shock/sepsis                                              41    40
  Acute tubular necrosis[^b^](#tfn2){ref-type="table-fn"}   19    18
  Cancer                                                    10    10
  Tumor lysis syndrome                                      8     8
  MOF                                                       4     4
  Hepato-renal syndrome                                     4     4
  Other                                                     12    12
  Unknown[^c^](#tfn3){ref-type="table-fn"}                  6     6

*^a^One patient could have had more than one etiological factor: a combination of at least two factors has been seen in 43 patients (42% of the cases)*.

*^b^Acute tubular necrosis except nephrotoxic drugs and shock/sepsis*.

*^c^No aetiology has been formally identified*.

*MOF, multiple organ failure*.

Criteria to initiate RRT were as follow: blood pH \<7.3 (*n* = 28), (oligo)anuria (*n* = 17), uremia (*n* = 7), severe ionic abnormality (*n* = 6), water overload (*n* = 3), uremic encephalitis (*n* = 1), or a combination of these factors (*n* = 40). In one case, the precise indication for CVVHDF can not be retrospectively determined.

CVVHDF Therapy Outcomes {#S3-1}
-----------------------

Extra-renal replacement therapy was CVVHDF in 100 patients, CVVH (continuous veno-venous hemofiltration) and CVVD (continuous veno-venous dialysis) in 1 and 2 cases, respectively. Pre-dilution technique was applied in 54 cases, post-dilution in 35 cases and alternatively both in 12 cases. Median blood flow rate was 180 ml/min (range: 60--200). Median reinjection fluid rate was 28.6 ml/kg/h. The median cumulated overall hemofiltration duration was 34.5 h (range: 2--354 h). Complications of RRT were filter coagulation at least once (*n* = 32), hypotension (*n* = 3) and uncomplicated hemorrhage at the catheter insertion's site (*n* = 3).

Complete or partial (persistent abnormal creatinine value not requiring further RRT) ARF resolution was observed in 27 and 18 patients, respectively. No resolution, defined as required RRT at the time of death (*n* = 49), transfer in another hospital without ARF resolution (*n* = 2), or need for chronic dialysis (*n* = 7), was found in 58 patients.

Patient Survival Outcomes {#S3-2}
-------------------------

Among patients alive at hospital discharge, complete, partial, or absence of ARF resolution was observed in 20, 9, and 9 patients, respectively. Seven patients (18% of the patients alive at the hospital discharge) needed chronic dialysis. Of them, 2 had a multiple myeloma and 5 patients presented with a loco-regional (*n* = 3) or metastatic (*n* = 2) solid tumor. Five of them had prior renal disease: polycystic kidney (*n* = 2), myelomatous kidney (*n* = 1), or a chronic renal failure not requiring dialysis (*n* = 2).

The median duration of ICU and hospital stays were 9 days (range: 1--124 days) and 22 days (range: 1--155 days). Fifty patients died in the ICU and a further 15 in the general ward after ICU discharge. Thirty-eight patients were discharged alive from the hospital. The ICU mortality rate was 49% and the hospital mortality rate was 63%. The main causes of hospital death were multiple organ failure (*n* = 21), septic shock (*n* = 16), shock from another origin (*n* = 7), cancer (*n* = 6), ARF (*n* = 2).

Univariate analysis of prognostic factors for hospital mortality is reported in Table [3](#T3){ref-type="table"}. All significant variables and those with a *p*-value \<0.2 in univariate analysis were included in a multivariate analysis. Two variables were statistically independent pejorative prognostic factors for hospital mortality in multivariate analysis: the number of organ failure \[Odds ratio = 5.918; 95% confidence interval (CI) 2.184--16.038; *p* \< 0.001\] and hypoalbuminemia (Odds ratio = 3.341; 95% CI 1.229--9.077; *p* = 0.02).

###### 

**Prognostic factors for hospital mortality -- univariate analysis**.

                             Non-survivors        Survivors            *p*-value       
  -------------------------- -------------------- -------------------- --------------- ------------
  Hematological tumor        27 (77%)             8 (23%)                              
  Solid tumor                38 (55%)             30 (45%)             **0.034**       
  Age (median)               61 years             64 years             0.06            
  Number of organ failure                                                              
   1                         10 (29%)             24 (71%)             **\<0.00001**   
   \>1                       55 (80%)             14 (20%)                             
  Cancer status                                                                        
   Progression               22 (67%)             11 (33%)             0.60            
   Other than progression    43 (61%)             27 (39%)                             
  Cancer phase                                                                         
   Diagnostic                6 (67%)              3 (33%)              0.23            
   Curative                  21 (51%)             20 (49%)                             
   Controllable              38 (72%)             15 (28%)                             
  Immunodepression           No                   29 (55%)             24 (45%)        0.07
  Yes                        36 (72%)             14 (28%)                             
  ARF origin                 Renal                51 (61%)             32 (39%)        0.43
  Mixed                      13 (68%)             6 (32%)                              
  Allo/auto graft            No                   49 (58%)             36 (42%)        **0.01**
  Yes                        16 (89%)             2 (11%)                              
  ARDS                       No                   47 (56%)             37 (44%)        **0.001**
  Yes                        18 (95%)             1 (5%)                               
  Mechanical ventilation     No                   22 (44%)             28 (56%)        **0.0001**
  Yes                        43 (81%)             10 (19%)                             
  Vasopressor                No                   30 (50%)             30 (50%)        **0.002**
  Yes                        35 (81%)             8 (19%)                              
                                                                                       
                             **Median (range)**   **Median (range)**                   
                                                                                       
  SAPS II                    57 (28--99)          50 (26--88)          **0.022**       
  Bilirubinemia (mg/dl)      1.4 (0.2--19)        0.5 (0.1--5.7)       **0.0002**      
  Creatininemia (mg/dl)      3.6 (1.3--18)        4.8 (1.3--20)        **0.02**        
  Uremia (mg/dl)             147 (55--492)        154 (49--485)        0.78            
  Natremia (mEq/l)           139 (122--150)       135 (128--148)       **0.01**        
  Kaliemia (mEq/l)           4.7 (3.2--8)         4.5 (2.9--7.8)       0.33            
  Phosphatemia (mEq/l)       6.2 (2.9--11.3)      6.1 (2.6--14.6)      0.80            
  Bicarbonate (mEq/l)        19 (6--32)           19 (3--27)           0.64            
  INR                        1.45 (0.97--3.9)     1.33 (0.8--2.9)      0.15            
  Albuminemia (g/dl)         2.5 (0.7--4)         3.05 (1.7--5.1)      **0.0001**      
  Leukocytes (10^3^/mm^3^)   7.8 (0.02--39)       13 (0.05--50)        0.07            

*SAPS, Simplified acute physiology score; INR, international normalized ratio; ARF, acute kidney injury; ARDS, acute respiratory distress syndrome*.

*Bold font highlight the significant variables in univariate analysis*.

At the time of analysis, 90 patients died, and 3 patients were lost to follow up. Median survival of patients discharged alive from hospital was 413 days; it was 157 days for patients on chronic dialysis but 441 days for those independent from dialysis (*p* = 0.34).

Discussion {#S4}
==========

In this retrospective study including patients with cancer with ARF requiring RRT, two statistically significant independent prognostic factors for hospital mortality were identified. A higher risk of death was associated with increasing number of organ failures and with low albumin levels. Cancer characteristics and SAPS II score were not associated with outcome.

This study confirms that CVVHDF is a feasible and well-tolerated RRT in patients with cancer with ARF admitted to the ICU. Prognosis was comparable to previously published studies (Table [4](#T4){ref-type="table"}). Detailed comparisons between studies are difficult due to different case-mix, indications and methods of RRT.

###### 

**Summary of publications assessing renal replacement therapy in patients with cancer admitted into ICU**.

  Reference                                                                                      Population            *N*               RRT                       Mortality           Prognostic factors for hospital mortality
  ---------------------------------------------------------------------------------------------- --------------------- ----------------- ------------------------- ------------------- ---------------------------------------------------------------------
  **Mixed population (solid and hematological tumors, including bone marrow transplantation)**                                                                                         
  Berghmans et al. ([@B15])                                                                      Solid: 50%            32                CVVHDF                    ICU: 50%            Number of organ failure
  Hemato: 50%                                                                                    Hospital: 53%                                                                         
  BMT: 28%                                                                                                                                                                             
  Salahudeen et al. ([@B5])                                                                      Solid: 38%            199               C-SLED                    Day 30: 65%         SOFA score, pH, mean blood pressure
  Hemato: 62%                                                                                                                                                                          
  BMT: 18%                                                                                                                                                                             
  **Mixed population (solid and hematological tumors, excluding bone marrow transplantation)**                                                                                         
  Maccariello et al. ([@B13])                                                                    Solid: 73%            118               IRRT daily conventional   ICU: 70%            Number of organ failure
  Hemato: 27%                                                                                    IRRT daily extended   Hospital: 78%                                                   
  CRRT                                                                                                                                                                                 
  Darmon et al. ([@B7])                                                                          Solid: 7%             94                CRRT                      ICU: 43.6%          LOD score, late RRT (\>24 h after ICU admission)
  Hemato: 78%                                                                                    IRRT                  Hospital: 51.1%                                                 
  Other: 15%                                                                                     6 months: 65.4%                                                                       
  Soares et al. ([@B14])                                                                         Solid: 75%            98                IRRT conventional         Hospital: 64--86%   --
  Hemato: 25%                                                                                    IRRT extended                                                                         
  CRRT                                                                                                                                                                                 
  **Hematological tumors**                                                                                                                                                             
  Letourneau et al. ([@B12])                                                                     BMT: 100%             14                CVVHDF                    --                  --
  IRRT                                                                                                                                                                                 
  Lanore et al. ([@B11])                                                                         BMT: 11%              43                                          ICU: 72%            ARF secondary to sepsis, SAPS score, mechanical ventilation support
  Benoit et al. ([@B9])                                                                          BMT: 22.4%            50                IRRT                      ICU: 79.6%          --
  CRRT                                                                                           Hospital: 83.7%                                                                       
  6 months: 86%                                                                                                                                                                        

Cancer series found by PubMed search using the MESH terms "Acute kidney injury" and "Intensive care."

*RRT, renal replacement therapy; CVVHDF, continuous venovenous hemodiafiltration; ICU, intensive care unit; C-SLED, sustained low efficiency dialysis in the continuous mode; CRRT, continuous renal replacement therapy; IRRT, intermittent renal replacement therapy; BMT, bone marrow transplantation; ARF, acute renal failure*.

As expected, higher mortality was observed when hematological malignancies are considered ([@B9]). Two prognostic factors for hospital mortality were highlighted that could be helpful in selecting patients for CVVHDF with better chance to be hospital discharged. The increased number of organ failures has yet been found associated with a pejorative prognosis as well in cancer and general populations ([@B7], [@B13], [@B15], [@B16], [@B20], [@B21]). On the opposite, the role of hypoalbuminemia was more controversial in general ICU ([@B22]--[@B25]) but was not extensively assessed in patients with cancer. A negative effect on mortality of hypoalbuminemia was shown in one study and only in univariate analysis ([@B16]). It must be emphasized that the cancer characteristics (status, phase or treatment) were not predictors of hospital mortality. As previously reported, hospital mortality was linked to acute physiological changes induced by the complications leading to ICU admission while cancer variables influenced significantly survival after hospital discharge ([@B18], [@B26], [@B27]).

In addition to the effectiveness of CVVHDF in patients with cancer, this RRT showed also adequate tolerance in this frail population, often immunocompromised due to cancer or its treatment. This observation was rarely reported in the literature. Other authors assessing C-SLED (sustained low efficiency dialysis in the continuous mode) for RRT, reported complication due to hypocalcemia induced by citrate administration for anticoagulation ([@B16]). In another publication concerning hematological malignancies, no bleeding was observed despite severe thrombopenia and a catheter infection was documented in 5% of the patients ([@B11]). Patients and physicians need to know that a substantial number of RRT will lead to permanent chronic replacement therapy, despite the documented effectiveness and tolerability of CVVHDF. In our study, 18% of the patients discharged alive from the hospital required a chronic dialysis. This was in the range between 14 and 24%, which is not different from rates observed in cancer patients ([@B7], [@B13], [@B14]) and in general ICU populations ([@B28]). It must be emphasized that in our study, five out of these seven patients presented with underlying renal diseases that could have contributed to the final renal status.

In the present study, we observed that half of the patients were exposed to a nephrotoxic drug that could have played a role in ARF development. Among them, anticancer drugs or immunosuppressive agents, the latter in case of bone marrow grafting, have been documented in 18% of the cases. A number of anticancer treatments are known for their nephrotoxicity with different pathophysiological mechanisms as cisplatin, nitrosourea derivatives, mitomycin, ifosfamide, or methotrexate without being exhaustive. Different preventive methods as adequate hydration (cisplatin) or urine alkalinization (high dose methotrexate) are recommended. Clinicians have to be aware of the poor prognosis of ARF when prescribing potentially nephrotoxic chemotherapy in patient with disturbed renal function and/or at risk for ARF. They also have to consider the risk of ARF when administering nephrotoxic agents after a nephrotoxic chemotherapy as iodine contrast product and/or aminoglycoside after cisplatin administration.

Potential Bias and Limitations {#S4-1}
------------------------------

Some bias related to retrospective studies must be discussed. As all the patients admitted to the ICU were prospectively recorded, a selection bias was unlikely. However, due to limited available data, some files have not been studied. The retrospective nature of our analysis could lead to missing data, which were minimal in our case. The number of patients in our study was limited but was in the same range as for the other publications. As for other unicentric studies, generalization of the results is limited. Nevertheless, our results and conclusion are comparable to previous series suggesting adequate robustness of the data ([@B13], [@B29]). Multiple definitions for ARF have been proposed. In this retrospective study, we decided, based on available data, to apply a simple definition of ARF (an increase of creatinine above 2 mg/dl). We did not use creatinine clearance or glomerular filtration rate because we were focusing on clinical settings where the clinicians decided performing RRT, most of the patients having high creatinine values and/or clinical signs of intolerance to ARF (acidosis, water overload ...). Our data could deserve further prospective study in which a more precise definition of ARF should be used as RIFLE criteria or other clearance determination.

In conclusion, although ARF requiring RRT in patients with cancer admitted in ICU still has a poor prognosis, the use of CVVHDF is effective and tolerable in this immunocompromised population. Multiple organ failure and hypoalbuminemia have to be considered when deciding to introduce RRT in the treatment of this group of patients.
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